Cargando…

P1596: PREDIAGNOSTIC ANTIMICROBIAL USE IN CLL, MM, FL AND DLBCL

Detalles Bibliográficos
Autores principales:	Packness, E. M., Andersen, M. A., Rostgaard, K., Hjalgrim, H., Niemann, C. U., Brieghel, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428973/ http://dx.doi.org/10.1097/01.HS9.0000849240.83690.64

Ejemplares similares

P859: PROGNOSTIC IMPACT OF OPIOID USE PRIOR TO DIAGNOSIS OF MULTIPLE MYELOMA
por: Brieghel, Christian, et al.
Publicado: (2023)

P603: INFECTIONS BEFORE AND DURING IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.
por: Brieghel, Christian, et al.
Publicado: (2023)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data
por: Parviz, Mehdi, et al.
Publicado: (2022)

Transformation of FL into DLBCL with a PMBL gene expression signature
por: Loveday, Tristan, et al.
Publicado: (2022)

P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL
por: Niemann, Carsten, et al.
Publicado: (2023)

American Society of Hematology 2020 Podcast Collection: FL and DLBCL
por: Fox, Christopher Paul, et al.
Publicado: (2021)

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
por: Niemann, Carsten U., et al.
Publicado: (2022)

IEEE P1596 (SCI) Working Group Meeting
Publicado: (1991)

1596. Ceftolozane/tazobactam (Zerbaxa) for the Treatment of Pseudomonas aeruginosa (PSA) Bacteremia: A Systematic Literature Review (SLR)
por: Dillon, Ryan J, et al.
Publicado: (2020)

The CLL comorbidity index in a population-based cohort: a tool for clinical care and research
por: Rotbain, Emelie C., et al.
Publicado: (2022)

P1596: EFFICACY AND SAFETY OF QL0911 IN ADULT PATIENTS WITH CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III TRIAL
por: Zhou, Hu, et al.
Publicado: (2023)

P1252: PREDICTING THE RESPONSE OF DLBCL CELLS TO BH3-MIMETICS USING SYSTEMS BIOLOGY
por: Cloete, I., et al.
Publicado: (2022)

Michelangelo Merisi da Caravaggio (1571–1610). Basket of Fruit (1596)
por: Potter, Polyxeni
Publicado: (2003)

Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients
por: da Cunha-Bang, C, et al.
Publicado: (2016)

The prediagnostic phase of Parkinson's disease
por: Noyce, Alastair John, et al.
Publicado: (2016)

1596P SERONCOVID: Seroconversion in solid-tumor cancer patients (p) after COVID-19 diagnosis
por: Pous, A., et al.
Publicado: (2021)

Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia
por: Rotbain, Emelie C, et al.
Publicado: (2021)

P1266: FLOW CYTOMETRY COMBINED WITH SYSTEMS BIOLOGY ENABLES RATIONAL TARGETING OF NFKB IN DLBCL
por: Jayawant, E., et al.
Publicado: (2022)

P817: VALIDATION OF THE SECOND REVISED INTERNATIONAL STAGING SYSTEM (R2-ISS) IN A LARGE POPULATION-BASED, NATIONWIDE COHORT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Brieghel, Christian, et al.
Publicado: (2023)

P1281: LIQUID BIOPSY PROVIDES COMPLEMENTARY INFORMATION TO TISSUE BIOPSIES FOR THE MOLECULAR CLASSIFICATION OF DLBCL PATIENTS
por: Moia, R., et al.
Publicado: (2022)

Machine learning can identify newly diagnosed patients with CLL at high risk of infection
por: Agius, Rudi, et al.
Publicado: (2020)

Socioeconomic position and prediagnostic health care contacts in children with cancer in Denmark: a nationwide register study
por: Pedersen, Line Hjøllund, et al.
Publicado: (2021)

Immediate COVID-19 treatment in CLL
por: Niemann, Carsten Utoft
Publicado: (2023)

P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
por: Jiang, Y., et al.
Publicado: (2022)

P1247: IDENTIFICATION AND VERIFICATION OF IMMUNE-RELATED GENE PROGNOSTIC SIGNATURE BASED ON SSGSEA FOR DLBCL
por: Shi, Wenyu
Publicado: (2023)

P1191: A NOVEL PROGNOSTIC MODEL OF DLBCL PATIENTS BASED ON CUPROPTOSIS RELATED GENES
por: Fu, LI, et al.
Publicado: (2023)

Prediagnostic Immune Cell Profiles and Breast Cancer
por: Kresovich, Jacob K., et al.
Publicado: (2020)

Prediagnostic serum 25-hydroxyvitamin D and melanoma risk
por: Stenehjem, Jo S., et al.
Publicado: (2020)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
por: Kater, Arnon, et al.
Publicado: (2023)

P985: CLL-1 IS AN ADOPTIVE IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA
por: Huebner, Juwita, et al.
Publicado: (2023)

P1246: CELL TYPE IDENTIFICATION USING MULTIPLEX IMMUNOFLUORESCENCE (MIF) GUIDED MACHINE LEARNING IN DLBCL
por: Chhor, Guillaume, et al.
Publicado: (2023)

P1175: THROMBOTIC RISK IN DLBCL: A REAL-LIFE COMPARISON OF THE THROLY AND MODEL IX SCORES
por: Civettini, Ivan, et al.
Publicado: (2023)

P869: PRODUCTION BY GUT MICROBIOTA AS PROGNOSTIC BIOMARKER IN MM
por: Rodríguez-García, A., et al.
Publicado: (2022)

P649: SAFETY AND EFFECTIVENESS IN NAIVE CLL PATIENTS TREATED WITH VEN AND OBI UNDER REAL-WORLD CONDITIONS - COMPARISON OF PATIENTS IN LINE OR OUT OF SCOPE WITH CLL14 TRIAL.
por: Ingo, Schwaner, et al.
Publicado: (2023)

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN
por: Munawar, U., et al.
Publicado: (2023)

Prediagnostic Plasma Metabolomics and the Risk of Exfoliation Glaucoma
por: Kang, Jae H., et al.
Publicado: (2022)

P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY.
por: Farina, M., et al.
Publicado: (2022)

P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
por: Vit, Filippo, et al.
Publicado: (2023)

P1299: LOSS OF TYROSINE PHOSPHATASE SHP1 SENSITIZES DLBCL TO IBRUTINIB: A CANDIDATE PREDICTIVE BIOMARKER
por: Wang, Y. L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6uas67suearkk18nklor6nkjh3